LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Pulmatrix Inc

Slēgts

5 1.21

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.86

Max

5.02

Galvenie mērījumi

By Trading Economics

Ienākumi

259K

-1.5M

EPS

-0.42

Peļņas marža

-60,266.667

Darbinieki

2

EBITDA

260K

-1.5M

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-2.1M

18M

Iepriekšējā atvēršanas cena

3.79

Iepriekšējā slēgšanas cena

5

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. sept. 22:39 UTC

Iegādes, apvienošanās, pārņemšana

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

2025. g. 15. sept. 16:43 UTC

Galvenie tirgus virzītāji

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

2025. g. 15. sept. 16:42 UTC

Galvenie tirgus virzītāji

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

2025. g. 15. sept. 16:35 UTC

Galvenie tirgus virzītāji

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

2025. g. 15. sept. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. sept. 23:46 UTC

Tirgus saruna

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

2025. g. 15. sept. 23:34 UTC

Tirgus saruna

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

2025. g. 15. sept. 22:48 UTC

Tirgus saruna

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

2025. g. 15. sept. 22:12 UTC

Iegādes, apvienošanās, pārņemšana

CSL Expects Commercial Launch in 2029

2025. g. 15. sept. 22:12 UTC

Iegādes, apvienošanās, pārņemšana

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

2025. g. 15. sept. 22:11 UTC

Iegādes, apvienošanās, pārņemšana

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

2025. g. 15. sept. 22:11 UTC

Iegādes, apvienošanās, pārņemšana

CSL to Have Right to Exercise Option Based on Phase 3 Data

2025. g. 15. sept. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

2025. g. 15. sept. 21:16 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

2025. g. 15. sept. 21:16 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

2025. g. 15. sept. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy to Buy 48,000 Net Acres in the Williston Core

2025. g. 15. sept. 21:14 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

2025. g. 15. sept. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 15. sept. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 15. sept. 19:29 UTC

Tirgus saruna

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

2025. g. 15. sept. 19:14 UTC

Tirgus saruna

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

2025. g. 15. sept. 18:16 UTC

Tirgus saruna

Gold Powers to New High -- Market Talk

2025. g. 15. sept. 18:05 UTC

Tirgus saruna

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

2025. g. 15. sept. 17:50 UTC

Iegādes, apvienošanās, pārņemšana

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

2025. g. 15. sept. 17:10 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. sept. 17:10 UTC

Tirgus saruna

S&P Expects Fed, BOC to Cut Rates -- Market Talk

2025. g. 15. sept. 16:52 UTC

Tirgus saruna

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

2025. g. 15. sept. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. sept. 16:20 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
help-icon Live chat